© Globe Newswire
08.12.2025
SGRY
LISTED
NASDAQ
Surgery Partners and Baylor Scott & White Health Form Joint Venture to Expand Access to Quality Care
News Preview
The Physicians Centre Hospital in Bryan to become a Baylor Scott & White facility, as health system grows to keep up with population increase in the Brazos Valley The Physicians Centre Hospital in Bryan to become a Baylor Scott & White facility, as health system grows to keep up with population increase in the Brazos Valley...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.12.2025
JAGX
LISTED
NASDAQ
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
News Preview
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerInitial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to m...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
LLY
LISTED
NYSE
Carolyn Bertozzi returns to Lilly board of directors
News Preview
INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees."On behalf of Lilly and the entire board, I would like to welcome Carolyn...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
08.12.2025
CSBR
LISTED
NASDAQ
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
News Preview
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the resul...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
08.12.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - von First Berlin Equity Research GmbH
08.12.2025 / 15:50 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CGEM
LISTED
NASDAQ
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
News Preview
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
News Preview
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
News Preview
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
CPIX
LISTED
NASDAQ
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
News Preview
NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for ma...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ABT
LISTED
NYSE
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
News Preview
Lingo, Abbott's first over-the-counter biowearable, expands to Android devicesContinuous glucose monitoring devices help people maintain healthy glucose levels, which are associated with better metabolic health and lower long-term risk of chronic conditionsNew data from Lingo users highlight how protein supplementation is linked to lower glucose i...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
VNRX
LISTED
XASE
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
News Preview
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
328130
LISTED
KOE
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
News Preview
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programsSEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that it has submitted a 510(k) premarket notification to th...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
08.12.2025
AFX
LISTED
XETR
Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme des Vorstandsvorsitzes durch Andreas Pecher zum 01.01.2026
News Preview
Beendigung der Vorstandstätigkeit von Maximilian Foerst zum 31.12.2025 und interimistische Übernahme des Vorstandsvorsitzes durch Andreas Pecher zum 01.01.2026 – interimistische Übernahme des Aufsichtsratsvorsitzes durch Peter Kameritsch
Jena, 08. Dezember 2025
Der Aufsichtsrat der Carl Zeiss Meditec AG (ISIN: DE0005313704) und Maximilia......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
AFX
LISTED
XETR
Termination of Maximilian Foerst’s Executive Board mandate as of 31 December 2025 and interim assumption of the CEO role by Andreas Pecher as of 1 January 2026
News Preview
Termination of Maximilian Foerst’s Executive Board mandate as of 31 December 2025 and interim assumption of the CEO role by Andreas Pecher as of 1 January 2026 –
interim assumption of the Chairmanship of the Supervisory Board by Peter Kameritsch
Jena, 8 December 2025
The Supervisory Board of Carl Zeiss Meditec AG (ISIN: DE0005313704) ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
HBMN
LISTED
SIX
Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen
News Preview
HBM Healthcare Investments AG
/ Schlagwort(e): Ankauf/Partnerschaft
Mirum Pharmaceuticals übernimmt HBM Portfoliounternehmen Bluejay Therapeutics für bis zu USD 820 Millionen
08.12.2025 / 14:50 CET/CEST
Die auf den Healthcare-Sektor fokussierte Beteiligungsgesellschaft HBM Healthcare Investments teilt mit, dass die Akti......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
HBMN
LISTED
SIX
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
News Preview
HBM Healthcare Investments AG
/ Key word(s): Acquisition/Partnership
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
08.12.2025 / 14:50 CET/CEST
HBM Healthcare Investments, an investment company focused on the healthcare sector, announces that the shareholders of its......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.12.2025
ONCO
LISTED
NEO
Onco-Innovations strebt Cross-Listing an der “Nasdaq” sowie eine mögliche begleitende Eigenkapitalfinanzierung an
News Preview
EQS-Media / 08.12.2025 / 14:35 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass es eine US-Investmentbank als Kapitalmarktberater beauftragt hat, um mit seiner Absicht eine mögliche zusätzliche Notierung (Cross-Listing) an der “Nasdaq Stock Market LLC” anzustreben u......
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
GLMD
LISTED
NASDAQ
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
News Preview
Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol and regorafenib" to be presented with a poster on December 9 at 3pm (HST).RAMAT-GAN, Israel, Dec. 8, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Lt...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
STAA
LISTED
NASDAQ
Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
News Preview
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffirmed its recommendation that shareholders vote “AGAINST” the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (N...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
HITC
LISTED
OTC
SafeSpace Global (SSGC) Announces Strategic Partnership With 911inform to Transform School Safety Across America
News Preview
Knoxville, TN, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to partner with 911inform, the nation’s most advanced emergency response and building intelligence platform protecting more than 13,000 facilities nationwide....
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting,...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants wi...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
TRUL
LISTED
CSE
Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$368,000,000 principal amount of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788CAD6 / I...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
TRUL
LISTED
CSE
Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$368,000,000 principal amount of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788C...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
RMD
LISTED
NYSE
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
News Preview
Resmed received FDA Clearance for Personalized Therapy Comfort Settings, to be marketed as Smart Comfort....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SANA
LISTED
NASDAQ
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
News Preview
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology ...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NPCE
LISTED
NASDAQ
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
News Preview
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the tr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
BRKR
LISTED
NASDAQ
Bruker Announces the Addition of Diagnostics Industry Leader Jack Phillips to its Board of Directors as of January 2026
News Preview
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry.
This press release features multimedia. View...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
CON
LISTED
NASDAQ
Concentra Expands to Corona, California
News Preview
Concentra® (NYSE: CON), the nation’s leader in occupational medicine, today announced the opening of a new medical center in Corona, California. The medical center, Concentra Corona, is conveniently located at 629 North Main Street, Unit C-3, Corona, California 92878.
“We’re excited to bring our medical services to Corona,” said Kathy Le, MD, sen...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
475830
LISTED
KOE
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
News Preview
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of preclinical data for ORM-1153 at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida. ORM-1153 i...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with B...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ONC
LISTED
NASDAQ
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
OMCL
LISTED
NASDAQ
Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management
News Preview
Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, today announced the launch of Omnicell Titan XT, a transformational, enterprise version of automated dispensing systems (ADS). Designed to unify proven automation and powerful intelligence, Titan XT will deliver an enhance...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
STAA
LISTED
NASDAQ
STAAR Surgical Announces Expiration of Go-Shop Period
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the previously announced go-shop period pursuant to STAAR’s amended merger agreement with Alcon Inc. (SIX/NYSE: ALC). The go-shop period expired at 11:59 p.m...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HURA
LISTED
NASDAQ
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
News Preview
Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced immunosuppression Data presented in the Company's poster demonstr...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric relapsed or refractory (r/r) B-ALL patients was presented at ASH 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IAN
LISTED
CSE
iAnthus Continues Expansion in Florida with the Opening of GrowHealthy’s 25th Dispensary in St. Petersburg
News Preview
iAnthus Continues Expansion in Florida with the Opening of GrowHealthy’s 25th Dispensary in St. Petersburg...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IRMD
LISTED
NASDAQ
IRADIMED Announces Special Cash Dividend of $0.50 Per Share
News Preview
ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ERNA
LISTED
NASDAQ
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
News Preview
Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignancies Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the pote...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characteriz...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GERN
LISTED
NASDAQ
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
News Preview
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
WELL
LISTED
TSX
WELL Subsidiary WELLSTAR Technologies Closes $62M Financing to Support Its Pre-Spinout Growth Strategy
News Preview
Not for distribution to U.S. news wire services or dissemination in the United States
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (“WELL”), a digital healthcare company focused on improving health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its majorit...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in dri...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
MRK
LISTED
NYSE
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program
News Preview
KIRKLAND, QC, Dec. 8, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eli...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driv...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
ACB
LISTED
NASDAQ
Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand
News Preview
NASDAQ | TSX: ACBEDMONTON, AB, Dec. 8, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving gro...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
UCB
LISTED
EURONEXT
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
News Preview
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic Improvement: two of the three key secondary endpoints showed significantly greater number of patients demonstrated ≥50% reduction in CMSF from basel...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
KPTI
LISTED
NASDAQ
Karyopharm to Participate in Baird's Biotech Discovery Series
News Preview
NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday,...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ALSAF
LISTED
EURONEXT
SAFE - Mise à disposition du Rapport Financier Semestriel 2025
News Preview
Mise à disposition du Rapport Financier Semestriel 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
NRIX
LISTED
NASDAQ
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
PRAX
LISTED
NASDAQ
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
News Preview
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002)...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FATE
LISTED
NASDAQ
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
News Preview
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GDTC
LISTED
NASDAQ
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
News Preview
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, inc...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
News Preview
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
SABS
LISTED
NASDAQ
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
News Preview
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FDMT
LISTED
NASDAQ
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will pr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
45680
LISTED
XJPX
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
News Preview
Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstracts at the 2025 San Antonio Breast Cancer Symposium (#SABCS25), which include four rapid fire mini-oral sessions and other presentations from five landmark trials of ENHERTU® (trastuzumab deruxt...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NWRN
LISTED
SIX
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the initiation of its ENIGMA-TRS 2 Phase III clinical study in the US, following approvals from the US Food and Drug Adm...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
